You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究降京東健康(06618.HK)目標價至45元 增長前景保持不變
匯豐研究發表報告指,京東健康(06618.HK)收入按年增長15%,符合預期。該行預計,藥品類別的增長將由今年第二季開始重新加速。用戶增長和ARPU上升是由集團增強用戶體驗所帶動。該行指其增長前景保持不變,對集團實現今年收入增加18%的預測仍然充滿信心。 該行表示,雖然京東健康正積極探索其他新業務,但目前收入貢獻仍很小。該行認為,這些新業務可能會令利潤受壓,但鑑於去年淨利潤好於預期及公司有效管理成本,該行將今明兩年non-IFRS淨利潤預測分別提高5%和14%,目標價由48元下調至45元,維持「買入」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account